Back to search

Article

Multi-omics joint analysis to explore new therapeutic targets for Crohn's disease

2023-08-17

Abstract excerpt

<h4>Background: </h4> Infliximab (IFX), the mainstay of current treatment for moderate-to-severe Crohn's disease (CD), markedly improved clinical symptoms and quality of life for patients. However, not all patients can benefit from IFX. This study aims to identify new therapeutic targets for primary nonresponders through combination of transcriptomic and proteomic analyses. Methods The plasma and peripheral leuko...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f4d022c7-b959-5966-979c-e8601c1b1b8b
DOI
10.21203/rs.3.rs-3241938/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multi-omics joint analysis to explore new therapeutic targets for Crohn's diseaseDOI 10.21203/rs.3.rs-3241938/v1
Select a neighboring publication to make it the new centre.